Sanger spinoff nabs $30M for "Kymouse"

Just a few months after stepping down as director of the prestigious Sanger Institute in the UK, Professor Allan Bradley has snared a $30 million venture round from The Wellcome Trust to finance a biotech he founded which promises to develop a better monoclonal antibody with the help of a genomically engineered mouse. Bradley, an internationally recognized genomics expert, helped develop a mouse model "that captures, in its engineered chromosomes, the entire diversity of the B lymphocyte component of the human immune system," says a release from the new biotech, Kymab. Release | Report

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.